GH therapy plays ‘neutral role’ on recurrence of pituitary t
In a retrospective, observational study, data was analyzed from 283 patients with adult GH deficiency with a confirmed histological diagnosis of NFPA (n = 194) or craniopharyngioma (n = 89) who underwent surgery between 1995 and 2018. Within the cohort, 123 patients opted for GH treatment at a median of 14 months after the index surgery (43.5%), with the remaining patients serving as controls. Median radiological follow-up for the cohort was 88 months.

Primary outcome was the risk for tumor recurrence in GH-treated and control patients. In univariate analysis, recurrence of the pituitary tumor was less frequent among GH-treated individuals (19.5%) than among controls (29.7%).

In multivariate Cox analysis, researchers found that the risk for tumor recurrence was associated with detection of residual disease at the baseline MRI, defined as the last MRI performed before the start of GH treatment or the first MRI after surgery among controls and with not having undergone radiotherapy, whereas GH treatment was no longer associated with a lower risk of growing evidence that GH therapy has a neutral effect on the recurrence of pituitary tumors

Once assured that GH therapy is not increasing the risk for tumor recurrence, the next question might be whether GH therapy may be continued without interruption while implementing the therapeutic strategy, ie, surgery and/or radiotherapy, to control the growth of the tumor.